Efficacy of the Spinal Cord Stimulation System as Salvage Therapy
Launched by BOSTON SCIENTIFIC CORPORATION · Oct 10, 2006
Trial Information
Current as of October 22, 2025
Terminated
Keywords
ClinConnect Summary
Chronic pain is managed by the sequential application of various strategies: medications, anesthetic injections, ablation, surgery, implantable intraspinal infusion pumps, and spinal cord stimulation. For a significant number of patients, however, these treatments are inadequate or cannot be tolerated. Those patients require another option for pain relief.
The therapy afforded by spinal cord stimulators is dependent on overlapping paresthesia with the painful areas. One of the leading reasons for explant of SCS systems (not including device failure or surgical complication) is the complain...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Have chronic and intractable neuropathic pain of the trunk and/or limbs of moderate to severe intensity and have failed treatment with an intraspinal infusion pump or other SCS device. Determination of failure of treatment will be based on subject feedback. Subjects with an active intraspinal infusion pump but with inadequate pain control will be allowed to participate;
- • Be 18 years of age or older;
- • Be an appropriate candidate for the surgical procedures required for this study;
- • Be willing and able to comply with all study related procedures and visits;
- • Be capable of reading and understanding patient information materials and giving written informed consent.
- Exclusion Criteria:
- • Have failed immediate past treatment with an intraspinal infusion pump or other SCS device because of technical reasons associated with the device such as unresolved lead migration, battery depletion, etc.;
- • Have any evidence of neurologic instability requiring surgery;
- • Have any significant medical condition that in the opinion of the investigator may interfere with the conduct of the study or may adversely affect the subject's safety during the study;
- • Have any other active implantable device with the exception of a intraspinal infusion pump for pain medications;
- • Are pregnant or lactating or planning to become pregnant in the next year;
- • Have participated in any investigational drug or device trial in the last 4 weeks or plan to participate in any other investigational drug or device trial while on this study.
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Napa, California, United States
Patients applied
Trial Officials
Roshini Jain
Study Director
Boston Scientific Neuromodulation Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials